Caption Management LLC Acquires New Stake in Bausch + Lomb Co. (NYSE:BLCO)

Caption Management LLC purchased a new stake in Bausch + Lomb Co. (NYSE:BLCO - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 25,674 shares of the company's stock, valued at approximately $464,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock valued at $48,000 after acquiring an additional 1,004 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Bausch + Lomb in the fourth quarter worth approximately $72,000. Commonwealth Equity Services LLC acquired a new stake in shares of Bausch + Lomb in the fourth quarter worth approximately $181,000. Alpine Global Management LLC acquired a new stake in shares of Bausch + Lomb in the fourth quarter worth approximately $181,000. Finally, Covestor Ltd purchased a new position in Bausch + Lomb in the fourth quarter valued at approximately $188,000. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Bausch + Lomb Price Performance

BLCO traded up $0.77 on Monday, reaching $12.04. The stock had a trading volume of 650,563 shares, compared to its average volume of 650,072. Bausch + Lomb Co. has a fifty-two week low of $10.45 and a fifty-two week high of $21.69. The firm has a 50-day moving average of $13.45 and a 200-day moving average of $16.54. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $4.25 billion, a price-to-earnings ratio of -13.24, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.10). The company had revenue of $1.15 billion during the quarter, compared to the consensus estimate of $1.15 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The company's quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.07 EPS. As a group, sell-side analysts anticipate that Bausch + Lomb Co. will post 0.74 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on BLCO. Royal Bank of Canada dropped their price target on shares of Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, April 4th. Bank of America cut their price objective on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating on the stock in a report on Thursday, February 20th. Stifel Nicolaus lowered their price target on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating for the company in a research note on Thursday, April 3rd. Evercore ISI reduced their price objective on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating for the company in a research report on Thursday, May 1st. Finally, Wells Fargo & Company dropped their price objective on Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $15.50.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.